Skip to content

West China psychiatric disorders registration study

The prediction of Plasma Tau and Abeta for psychiatric disorders and its relationship with brain images

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2000041484
Enrollment
Unknown
Registered
2020-12-27
Start date
2020-12-27
Completion date
Unknown
Last updated
2021-03-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Schizophrenia, depression, bipolar disorder

Interventions

Schizophrenia, depression, bipolar disorder, control group:Nil

Sponsors

West China Hospital, Sichuan University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1) First/recurrent hospitalized patients; 2) Meet clinical diagnostic criteria for schizophrenia, based on the assessment using the structured clinical interview (SCID) for DSM-IV-TR; 3) Currently between 18 to 45 years old; 4) The total score of the positive and negative symptom scale (PANSS) >= 60 points (1-7 point version), of which at least 3 items having a score >= 4 points; 5) Signed the written informed consent. If the patient is deemed incapacitated by illness, the written informed consent of the legal guardian is required.

Exclusion criteria

Exclusion criteria: 1) Meet the diagnostic criteria of DSM-IV for schizoaffective disorder, mood disorder, mental retardation (intellectual disability), generalized developmental disorder, delirium, dementia, memory impairment or other cognitive impairments; 2) Severe unstable physical illness; diagnosed diabetes, thyroid disease, hypertension, heart disease, etc.; 3) Angle-closure glaucoma; 4) History of epilepsy, not including that of febrile seizures; 5) Meet the diagnostic criteria of DSM-IV-TR for substance abuse (except for nicotine dependence); 6) Used long-acting antipsychotics in the previous treatment interval (minimal 5 weeks of wash-out period are required for RISPERDAL CONSTA); 7) Regular use of clozapine within one month prior to the enrollment; 8) Used ECT treatment one month before the enrollment; 9) History of Neuroleptic Malignant Syndrome (NMS) and severe tardive dyskinesia; 10) Currently have serious suicide attempts and agitation; 11) The presence of abnormal clinical laboratory findings (i.e. A serum AST/ALT level equal to or more than 5 to 10 times the upper limit of normal value; a BUN level equal to or more than 1.5 times the upper limit; a serum Cr level equal to or more than 1.2 times the upper limit); 12) Unable to follow the treatment plan and no available legal guardian; 13) ECG corrected-QTc interval >= 450 milliseconds for male, >= 470 milliseconds for female); 14) Current pregnancy or lactation, or recent plan for pregnancy; 15) Poor efficacy against three adequate trials of antipsychotics in the past (two of which have a different pharmacological mechanism; poor efficacy herein is defined as the presence of severe symptoms with poor social and work function); 16) The presence of contraindications for the antipsychotics used in this study.

Design outcomes

Primary

MeasureTime frame
Tau;Ptau181;Abeta;MRI Scan;Outcome: Positive and Negative Syndrome Scale;Clinical Global Impression Scale;A Rating Scale for Extrapyramidal Side Effects;Barnes Akathisia Rating Scale;IQ;

Countries

Chna

Contacts

Public ContactPeng Lei

West China Hospital of Sichuan University

peng.lei@scu.edu.cn+86 15882450747

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026